Feline Coronavirus and FIP: Virology Reference

Overview and Taxonomy of Feline Coronavirus

Feline coronavirus (FCoV) occupies a distinctive and complex niche within the family Coronaviridae, subfamily Orthocoronavirinae, and order Nidovirales. As noted by Horzinek, coronaviruses are “not only the largest RNA viruses, but also those with the largest genomic RNA molecules known to science,” a feature that raises fundamental questions about the evolutionary advantage of such expansive genetic cargo [18]. Within the feline host, FCoV exists as two discrete biotypes: the ubiquitous and largely benign feline enteric coronavirus (FECV) and the highly lethal feline infectious peritonitis virus (FIPV). The transition from FECV to FIPV is the central enigma of feline coronavirus biology, a mutation-driven shift in cellular tropism that transforms a mild enteric pathogen into a systemic, immunopathologic killer. Understanding the taxonomy and overview of FCoV is therefore not merely an exercise in classification; it is the foundation upon which all subsequent virologic, diagnostic, and therapeutic advances rest.

Taxonomic Position and Nidovirus Architecture

FCoV is classified within the genus Alphacoronavirus, species Alphacoronavirus 1, which also encompasses canine coronavirus (CCV) and transmissible gastroenteritis virus of swine. The Nidovirales order is defined by a conserved replication strategy involving discontinuous transcription of a 3′-coterminal nested set of subgenomic mRNAs, a mechanism from which the order derives its name (nidus, Latin for nest) [18]. This transcriptional program produces a characteristic set of structural proteins: the spike (S) glycoprotein, membrane (M) protein, small envelope (E) protein, and nucleocapsid (N) protein. Trimers of the S protein form the peplomers responsible for host cell receptor attachment and membrane fusion, and these same peplomers are the primary targets of the host humoral immune response and the sites of critical virulence-altering mutations [5, 18]. The FCoV genome, approximately 30 kb in length, is a single-stranded, positive-sense RNA molecule, a size that provides ample opportunity for recombination and mutation, the very processes that drive the FECV-to-FIPV leap [1, 13].

Serotypes and Genotypes: FCoV Type I and Type II

FCoV exists as two distinct serotypes, designated type I and type II, which differ substantially in their spike protein sequences and receptor usage. Type I FCoV is the predominant genotype circulating in natural feline populations worldwide, as exemplified by studies in Italy, the United States, and Indonesia [3, 5, 7]. Type II FCoV is rarer and arose through recombination events between type I FCoV and canine coronavirus, yielding a chimeric spike protein that confers altered cell tropism [9, 11]. In a cohort of naturally occurring FIP cases studied by Murphy et al., all viral isolates subjected to genotyping were serotype I [7]. This dominance of type I is significant because it means that most commercially available diagnostic assays, vaccine candidates, and experimental therapeutics must contend with a genotype that is more recalcitrant to in vitro culture and more genetically diverse than its type II counterpart. Moreover, the two serotypes are not simply antigenic variants; their differences in receptor binding profoundly influence pathogenesis and the host immune response [11].

The FECV–FIPV Biotype Distinction: Mutation and Adaptation

The central paradigm of FCoV biology holds that FIPV arises from FECV through the acquisition of specific mutations in individual cats, a process termed the “internal mutation hypothesis.” This hypothesis is supported by phylogenetic analyses showing that FECV and FIPV sequences from the same animal are closely related, often clustering together on phylogenetic trees regardless of biotype [5, 8]. Decaro et al. documented that two amino acid substitutions in the spike protein, M1058L and S1060A, are strongly associated with FIPV isolates in Italian cats, with M1058L present in 16 of 18 type I FIPV strains and the single type II FIPV strain analyzed [5]. These mutations are believed to enhance the ability of the virus to replicate in monocytes and macrophages, thereby enabling systemic dissemination, a critical step in FIP pathogenesis [9, 11].

However, the internal mutation hypothesis is not the sole explanation for the emergence of virulent strains. Hora et al. examined the molecular diversity of the FCoV membrane (M) gene in cats with and without FIP and found evidence supporting both the internal mutation model and a “circulating high-virulence/low-virulence” hypothesis. In one cat, two distinct FCoV lineages, one enteric and one systemic, were identified that segregated apart in the M gene tree, suggesting that some FIPV strains may circulate as distinct variants in the environment rather than arising de novo in each host [8]. This dual-pathway concept has profound implications for epidemiology and control: if virulent strains can be transmitted directly, then targeted management of sheltter populations becomes more urgent. The emergence of the novel FCoV-23 variant during the 2023 Cypriot epizootic, which was temporally associated with a marked increase in FIP cases, including a higher proportion of neurological presentations, further underscores the potential for emergent, highly virulent lineages to spread through cat populations [4].

Comparative Virology and Zoonotic Potential

FCoV shares fundamental virologic features with other coronaviruses, including the betacoronavirus SARS-CoV-2. Both viruses are enveloped, positive-sense RNA viruses that employ a discontinuous transcription strategy and encode a 3C-like protease (3CLpro) essential for viral polyprotein processing [2, 17]. Phylogenetic analyses have demonstrated that FIPV isolates can cluster with SARS-CoV-2 clades, reflecting ancestry within the broader Coronaviridae family [3]. While FCoV is not considered a zoonotic pathogen, the World Health Organization (WHO) and the U.S. Centers for Disease Control and Prevention (CDC) currently list no evidence of FCoV transmission from cats to humans, the close genetic relationship between animal and human coronaviruses warrants ongoing surveillance. The World Organisation for Animal Health (WOAH) includes FCoV in its list of notifiable diseases for felids due to its severe impact on feline welfare, and the Food and Agriculture Organization of the United Nations (FAO) recognizes the importance of monitoring coronaviruses in domestic animals as sentinels for potential spillover events [17].

Cellular Tropism and Pathotype Determinants

The switch from FECV to FIPV is fundamentally a shift in cellular tropism. FECV replicates primarily in mature enterocytes of the intestinal villi, causing mild or subclinical enteritis. In contrast, FIPV acquires the capacity to infect and replicate efficiently in monocytes and macrophages, leading to cell-associated viremia and systemic dissemination [9, 11]. This tropism switch is driven by mutations in the spike protein, in particular, the furin cleavage site and the fusion peptide region, that allow the virus to enter macrophages via a different receptor or through altered fusion requirements [5, 6]. Desmarets et al. provided experimental evidence that even FECV can establish a cell-associated viremia in the absence of robust intestinal replication, and that viral mutants with impaired infectivity for enterocytes can be shed in feces, raising the hypothesis that gradual adaptation to immune cells may precede the acquisition of full FIPV virulence [10]. This observation blurs the line between biotypes and suggests that the FECV–FIPV continuum is more fluid than previously appreciated.

Host genetic factors also modulate the outcome of FCoV infection. The feline leucocyte antigen (FLA) class II region, which governs antigen presentation, has been implicated in susceptibility to FIP. Preliminary studies by Addie et al. found no statistically significant association between specific FLA–DRB alleles and FIP development, but breed variation and small sample sizes limited the analysis [16]. Nevertheless, the fact that certain pedigree cats appear overrepresented in FIP cohorts, even after controlling for environmental exposure, points to an underlying genetic predisposition that may involve immune regulatory genes [16]. The interplay between viral mutation and host genetics remains one of the most poorly understood yet critical dimensions of FIP virology.

Diagnostic and Epidemiological Implications of Taxonomy

Because FECV and FIPV are genetically nearly identical and serologically cross-reactive, no single diagnostic test can reliably distinguish between the biotypes [9, 12]. The failure of current assays to differentiate the viruses stems from the lack of a universal “FIPV-specific” genetic marker that is present in all virulent strains and absent from all avirulent ones. Even spike mutations such as M1058L, although strongly associated with FIPV, are not absolute; some FIPV strains lack these changes, and some FECV strains may harbor them without causing disease [5, 11]. This ambiguity forces clinicians to rely on a constellation of clinical signs, clinicopathologic abnormalities, and detection of FCoV RNA in effusions or tissues using RT-PCR [7, 14]. The recent development of quantitative RT-PCR assays that target highly conserved regions of the FCoV genome (e.g., the 7b gene or the M gene) has improved sensitivity, but specificity for FIP remains a challenge because FCoV RNA can be detected in the blood of healthy carriers [15]. As Thayer and Gogolski emphasize, the diagnosis of FIP is built “brick by brick,” with each additional laboratory or clinical finding incrementally increasing the index of suspicion [14].

The taxonomic complexity of FCoV extends to the emerging recombinant strain FCoV-23, which was first identified in Cyprus during a large-scale FIP epizootic in 2023. Molecular characterization of FCoV-23 revealed a recombination event between a type I FECV backbone and a spike gene of unknown origin, resulting in a virus with enhanced neurotropism and a higher case fatality rate [4]. This finding challenges the traditional view that FIP is always an incidental outcome of random mutation within an individual cat; instead, it suggests that recombinant viruses with intrinsic virulence can circulate and cause outbreaks. The epidemiological data from Cyprus, including a mean age of affected cats at 3.9 years and a 35.3% rate of neurological signs, underscore the need for continuous molecular surveillance of FCoV in multi-cat environments [4].

In summary, the taxonomy and overview of feline coronavirus encompass a dynamic interplay between genotype, serotype, biotype, and host genetics. The virus’s large RNA genome, its propensity for mutation and recombination, and its dual biotype existence make FCoV a model for understanding coronavirus evolution and emergence. As the global veterinary community contends with the ongoing threat of FIP, and as lessons from FIP inform human coronavirus research, a thorough appreciation of FCoV virology remains indispensable.

Genomic Organization and Viral Replication of Feline Coronavirus

Feline coronavirus (FCoV) is a member of the family Coronaviridae within the order Nidovirales, a taxonomic designation that fundamentally distinguishes these viruses from all other RNA viruses based on their characteristic nested-set transcription strategy [18]. The FCoV genome is a single-stranded, positive-sense RNA molecule of approximately 30 kilobases in length, making it one of the largest RNA genomes known to virology [11, 18]. This genetic enormity is not merely a curiosity; it encodes a sophisticated repertoire of structural, non-structural, and accessory proteins that underpin both the virus's ubiquitous persistence in feline populations and its occasional lethal transformation into the agent of feline infectious peritonitis (FIP).

Structural and Non-Structural Gene Architecture

The FCoV genome is organized in a canonical coronavirus fashion: the 5′-two-thirds of the genome encompass two large open reading frames (ORF1a and ORF1b) that encode the replicase polyproteins pp1a and pp1ab, the latter produced via a programmed ribosomal frameshift [11]. These polyproteins are cleaved by viral proteases, including the 3C-like protease (3CLpro) and a papain-like protease, to yield an array of non-structural proteins that form the replication-transcription complex [2]. The 3CLpro of FCoV has been a target for structure-based virtual screening, with key active-site residues such as His162, Glu165, and Cys144 providing essential hydrogen-bonding and hydrophobic contacts for inhibitor binding [2]. The remaining one-third of the genome encodes the four canonical structural proteins: spike (S), envelope (E), membrane (M), and nucleocapsid (N), in that order from 5′ to 3′ [18]. Between these structural genes, several accessory ORFs are interspersed, most notably ORF3 (encoding proteins 3a, 3b, 3c) and ORF7 (encoding 7a and 7b), whose functions remain incompletely defined but are implicated in virulence modulation and host range [11].

The spike protein is the primary determinant of cell tropism and is the focus of intensive mutation analysis because of its central role in the avirulent-to-virulent biotype switch. In Italian FCoV sequences, two specific amino acid substitutions in the spike protein, M1058L and S1060A, have been statistically associated with the FIPV biotype [5]. These mutations likely alter the fusogenic properties of the S protein or its interaction with cellular receptors, thereby enabling the virus to replicate efficiently in macrophages and monocytes rather than being confined to intestinal epithelial cells [11]. Critically, phylogenetic analyses of FCoV sequences consistently show that FECV and FIPV strains cluster by genotype (type I or type II) rather than by biotype, and that isolates from the same cat are closely related [5, 8]. This genetic intimacy supports the "internal mutation hypothesis," wherein FIPV arises from a pre-existing FECV infection within an individual cat, rather than from transmission of a circulating virulent strain [8, 11].

Viral Replication and Discontinuous Transcription

The replication strategy of FCoV follows the nidovirus paradigm. Upon entry via spike-mediated attachment to host cell receptors, which for type I FCoV is thought to be feline aminopeptidase N, while type II uses a separate, less-defined entry pathway [11], the positive-sense genomic RNA is released into the cytoplasm and immediately translated to produce the replicase polyproteins. The replication-transcription complex then synthesizes full-length negative-sense genomic RNA, which serves as a template for new positive-sense genomes [18].

A defining hallmark of nidoviruses is discontinuous transcription, which produces a 3′-coterminal nested set of subgenomic mRNAs. During negative-strand synthesis, the polymerase pauses at transcription-regulatory sequences (TRSs) located upstream of each ORF, then jumps to the leader TRS at the 5′ end of the genome, generating a negative-sense template with a common 5′ leader sequence. These negative-strand templates are then used to produce positive-sense subgenomic mRNAs, each of which is effectively monocistronic [18]. This nested arrangement ensures that only the most 5′-proximal ORF on each mRNA is translated, allowing controlled expression of structural and accessory proteins from downstream genes. The process also generates genetic diversity: experimental infection of specific-pathogen-free cats with FECV strain UCD revealed that viruses shed in feces during the later stages of infection (14–56 days post-inoculation) carried mutations, particularly in the spike gene, and exhibited impaired infectivity in enterocyte cultures, suggesting that replicative errors are common [10].

Replication Sites and Cellular Tropism

The fundamental distinction between the benign FECV biotype and the lethal FIPV biotype lies in their cellular tropism. FECV replicates primarily in mature villous enterocytes of the small intestine, causing only mild or subclinical enteritis [11, 18]. In contrast, FIPV aquires the ability to replicate efficiently in cells of the monocyte/macrophage lineage. This shift is driven by mutations, most notably those in the spike protein, that allow the virus to enter and replicate within these immune cells, leading to systemic dissemination [11]. Once inside macrophages, FIPV replication triggers a profound immunopathological response: the infected cells become activated and produce a cascade of cytokines, contributing to the characteristic pyogranulomatous inflammation and effusive or non-effusive disease forms [11, 13].

Transcriptomic studies have elucidated the host response to FIPV replication. In Crandell Rees Feline Kidney (CRFK) cells infected with FIPV strain 79-1146, 61 genes were differentially expressed at 3 hours post-infection, with upregulation of genes associated with monocyte-macrophage function, Th1 responses, and apoptotic regulation [1]. Similarly, comparative transcriptome analysis of peripheral blood mononuclear cells from healthy, FIP-diseased, and FIP-recovered cats identified 677 and 431 differentially expressed genes between the respective groups, with notable involvement of neutrophil degranulation and IL-8 signaling pathways driven by upstream regulators KLF6 and NF-κB [13]. These patterns underscore the intense immune activation that accompanies FIPV replication in vivo.

An intriguing aspect of FCoV replication is the detection of viral RNA in blood cells even in the absence of intestinal replication. In one experimentally infected cat, FECV RNA was found in blood cells from 3 days post-infection, despite no fecal shedding until day 14, and the shed viruses carried mutations that rendered them non-enterotropic [10]. This observation suggests that FECV can directly infect immune cells, and that gradual adaptation to these cells may allow non-enterotropic, potentially FIP-causing mutants to arise even without a robust intestinal phase. These findings support a continuum hypothesis, reconciling the "internal mutation" and "circulating virulent strain" models [8, 10].

The genomic organization and replication mechanics of FCoV are not merely of academic interest; they have direct clinical and diagnostic implications. RT-PCR assays targeting conserved regions of the genome (e.g., the membrane or nucleocapsid genes) are widely used for FCoV detection, but they cannot distinguish between FECV and FIPV because these biotypes share the same genome sequence except for specific point mutations [12, 14]. The recent emergence in Cyprus of a novel recombinant FCoV (FCoV-23), associated with a large-scale FIP epizootic and an unusually high proportion of neurological presentations, underscores the plasticity of the FCoV genome and its capacity to generate variants with altered pathogenic potential through recombination and mutation [4]. Understanding the precise molecular events that trigger the biotype switch remains one of the most pressing challenges in coronavirology, with implications not only for feline medicine but also for the broader field of coronavirus evolution, including zoonotic threats such as SARS-CoV-2, which shares a similar genomic organization and replicative strategy [17]. The World Organisation for Animal Health (WOAH) recognizes the importance of monitoring FCoV in domestic and wild felids, as coronaviruses frequently shift hosts and recombination events can generate novel pathogens with pandemic potential [17].

Molecular Pathogenesis of FIP Virus: Virulence Determinants and Host Transcriptional Reprogramming

The transition from the ubiquitous, largely benign feline enteric coronavirus (FECV) to the lethal feline infectious peritonitis virus (FIPV) represents one of the most enigmatic and intensively studied phenomena in veterinary virology. This process, occurring within individual cats following initial FECV infection, is not a single, discrete event but rather a complex, multifactorial cascade involving discrete viral genetic mutations, shifts in cellular tropism, and a profound reprogramming of the host's transcriptional landscape. Understanding the molecular underpinnings of this biotypic switch is critical for deciphering why a ubiquitous pathogen triggers a fatal, immune-mediated disease in a subset of infected animals. The pathogenesis of FIP is therefore a story of two interwoven narratives: the viral determinants that confer the pathogenic phenotype and the host's molecular response that, when aberrant, becomes the primary driver of pathology.

Viral Virulence Determinants: The Genetic Basis of Biotype Conversion

The central dogma of FIP pathogenesis has long been the "internal mutation hypothesis," which posits that FIPV arises de novo within an infected individual from a pre-existing, avirulent FECV strain [8, 11, 18]. This hypothesis is supported by phylogenetic analyses showing that FECV and FIPV strains from the same animal are more closely related to each other than to strains from other cats, and that FCoV sequences cluster according to genotype (Type I vs. Type II) rather than biotype (FECV vs. FIPV) [5, 8]. This indicates that the switch to virulence is not a phylogenetic lineage acquisition but a series of somatic mutations occurring during persistent FECV replication.

The most critical genetic signatures identified to date reside within the gene encoding the spike (S) protein, the key determinant of cellular tropism. Seminal work has pinpointed two specific amino acid substitutions in the S protein: M1058L and S1060A [5]. In a survey of Italian FCoV strains, the M1058L mutation was detected in a striking 16 out of 18 Type I and 1 out of 1 Type II FIPV strains, while being absent in matched FECV strains from non-FIP cats [5]. These mutations are not merely passive markers; they are mechanistically linked to the acquisition of the ability to replicate efficiently within cells of the monocyte/macrophage lineage. This shift in tropism is the cornerstone of FIP pathogenesis. FECV primarily replicates in the differentiated epithelial cells of the intestinal villi, causing only a mild or subclinical enteritis. The acquisition of spike mutations, particularly in the region near the S1/S2 cleavage or fusion domain, is believed to alter the fusogenicity of the spike protein, enabling the virus to bind to and enter monocytes and macrophages more effectively, thereby establishing a systemic, cell-associated viremia [11, 14, 18].

However, the genetic story is more complex than a simple "one mutation, one disease" model. The membrane (M) gene also displays intra-host diversity, with a study by Hora et al. (2013) revealing random single nucleotide polymorphisms (SNPs) in the M gene of FCoVs from cats with FIP [8]. Crucially, this study found that in a single cat with FIP, two distinct viral lineages could be identified: one enteric and one systemic, which segregated apart in a phylogenetic tree of the M gene [8]. This lends direct evidence to the concept that the systemic, pathogenic FIPV lineage emerges from the enteric FECV population through sequential mutations. The experimental infection of specific-pathogen-free cats with FECV, as demonstrated by Desmarets et al. (2016), further refined this model. The study showed that while FECV shedding initially produced infectious virus, viruses shed later in infection were less infectious in enterocyte cultures and were affected by mutations [10]. More provocatively, in one cat without intestinal replication, the virus was detected in blood cells early on, and a "non-enterotropic, mutated" virus was shed later [10]. This suggests that the path to virulence may involve an intermediate stage of adaptation to immune cells, which can occur even in the absence of robust intestinal replication. The emergence of the novel FCoV-23 in Cyprus, which was associated with a large-scale FIP epizootic and a disproportionately high incidence of neurological signs, underscores that the mutational landscape driving virulence can shift, potentially involving recombination events that create new viral backbones with enhanced pathogenic potential [4].

Host Transcriptional Reprogramming: From Immune Dysregulation to Cellular Subversion

Once FIPV has breached the monocyte/macrophage barrier, the host's response is no longer a protective antiviral defense but a catastrophic, self-destructive immunopathologic process. The virus does not simply replicate; it actively rewires the transcriptional machinery of its target cells and the broader immune system. RNA sequencing of FIPV-infected CRFK cells at 3 hours post-infection identified 61 differentially expressed genes, with the majority clustered around functions associated with monocyte-macrophage and Th1 cell biology, as well as the regulation of apoptosis [1]. This early transcriptional hijacking sets the stage for the full-blown disease.

A hallmark of the host reprogramming in FIP is the induction of an exhausted and dysregulated T-cell response. Transcriptional profiling of peripheral blood mononuclear cells (PBMCs) from FIP-diagnosed cats has revealed a striking upregulation of immune checkpoint molecules, including programmed cell death protein 1 (PD-1) and its ligand PD-L1, as well as apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3H (A3H) [1]. These molecular signatures are not mere bystander effects; they are functional drivers of T-cell exhaustion. Mesenchymal stem/stromal cell (MSC) therapy combined with antiviral treatment has been shown to downregulate these inhibitory receptors (PD-1, TIM-3, LAG-3) and reduce the expression of exhaustion-related transcription factors such as IKZF2, ZEB2, and PRDM1 [19]. This indicates that the FIP viral infection actively pushes T-cells towards a state of functional paralysis, preventing the cytotoxic clearance of virus-infected macrophages. Single-cell RNA sequencing of mesenteric lymph nodes from treated cats further demonstrated a transcriptomic shift towards immune rejuvenation, with increased expression of memory T-cell markers (IKZF1, GZMK, IL7R) and a reduction in hyperproliferative lymphocyte subsets [19]. The parallels between this T-cell exhaustion in FIP and that seen in severe human coronavirus infections, such as COVID-19 caused by SARS-CoV-2, are striking and highlight FIP as an important translational model for studying viral-induced immune dysregulation [17, 19].

The activation of an uncontrolled, hyperinflammatory state is mediated through the NF-κB signaling pathway. Comparative transcriptome analysis of PBMCs from normal, FIP-diseased (FIPD), and FIP-recovered (FIPR) cats has identified a central role for interleukin-8 (IL-8) signaling and neutrophil degranulation pathways [13]. The transcription factor kruppel-like factor 6 (KLF6) was identified as an upstream regulator of IL-8, acting in concert with NF-κB to drive neutrophil activation and function [13]. This is a critical finding, as it links direct viral transcriptional control (potentially mediated by KLF6) to the massive, non-specific inflammatory cascade that characterizes the effusive ("wet") form of FIP, where high-protein effusions accumulate in body cavities due to increased vascular permeability and neutrophil infiltration. The aberrant neutrophil degranulation pathway suggests that the antiviral response is skewed away from a targeted T-cell response towards a destructive, innate inflammatory reaction.

Furthermore, the host's genetic makeup, specifically the feline leucocyte antigen (FLA) class II complex, plays a permissive role in determining the outcome of infection. The FLA-DRB locus, a highly polymorphic region central to antigen presentation to CD4+ T-helper cells, exhibits significant variation among cats. While a definitive susceptibility allele has not been identified, the sheer number and variation of FLA-DRB alleles present in individuals may contribute to the inability to mount an effective immune response against the mutated FIPV epitopes [16]. This genetic predisposition, combined with the virus's ability to replicate in and reprogram macrophages, effectively blindsides the adaptive immune system. The result is a transcriptional milieu characterized by a persistent anticoronaviral antibody response (primarily IgG against N and M proteins) that is ineffective at clearing the virus and may even contribute to antibody-dependent enhancement (ADE) of infection, a phenomenon also suspected in severe COVID-19 [7, 17]. The immune system is thus caught in a futile loop: it cannot eliminate the virus due to T-cell exhaustion and monocyte/macrophage tropism, yet it cannot stop its own hyperinflammatory response, leading to the fatal systemic disease of FIP.

Immunopathology and Host-Virus Interaction in Feline Infectious Peritonitis

Feline infectious peritonitis (FIP) is fundamentally an immunopathologic disease, not a classical cytolytic viral infection. The clinical trajectory from benign enteric coronavirus carriage to fatal systemic disease is determined by a delicate and often catastrophic interplay between the virulent FIP virus (FIPV) biotype and the host immune system. This interaction dictates whether an infected cat develops a protective, cell-mediated response leading to viral clearance, or a dysregulated, predominantly humoral response culminating in the systemic, fatal inflammation that characterizes FIP. The World Organisation for Animal Health (WOAH) recognizes FIP as a major cause of mortality in domestic and captive wild felids, and its complex pathogenesis has drawn renewed global attention given its striking parallels to severe human coronavirus disease (COVID-19), including shared mechanisms of antibody-dependent enhancement (ADE), cytokine storm, and T-cell exhaustion [17, 19].

The Viral Trigger: Myeloid Tropism and Mutation

The path to FIP begins with a radical shift in viral tropism. Feline enteric coronavirus (FECV) is confined to the apical enterocytes of the intestinal tract, causing a benign, often subclinical infection [11, 18]. The acquisition of macrophage tropism is the singular defining event that allows FECV to transform into FIPV [14, 18]. This shift is driven by mutations in the spike (S) glycoprotein. Decaro et al. [5] systematically analyzed Italian FCoV strains and identified two specific amino acid changes in the S protein, M1058L and S1060A, that were significantly associated with the FIPV biotype. These mutations, likely arising during the error-prone replication of the RNA genome, allow the virus to enter and replicate efficiently within monocytes and macrophages. The existence of viral quasispecies within a single host, as demonstrated by Hora et al. [8], provides the genetic reservoir from which these macrophage-tropic mutants emerge. Desmarets et al. [10] added a crucial nuance by showing that FECV can establish a cell-associated viremia even in the absence of robust intestinal replication, suggesting that the barrier between enterocyte and myeloid cell infection may be more permeable than previously thought. Further complicating this picture, the emergence of recombinant strains like FCoV-23 in Cyprus, which harbors a unique spike gene architecture, has been temporally associated with an epizootic marked by an increased prevalence of neurological signs [4]. This indicates that continuous viral evolution directly shapes the landscape of FIP immunopathology.

The Humoral Paradox: Antibodies and Antibody-Dependent Enhancement

A hallmark of FIP is the presence of high titers of anti-FCoV antibodies. Cats with FIP typically mount a robust humoral response, predominantly of the IgG isotype, targeting the structural nucleocapsid (N) and membrane (M) proteins [7, 20, 23]. However, this antibody response is not protective; it is profoundly pathogenic. This phenomenon is termed Antibody-Dependent Enhancement (ADE). Instead of neutralizing the virus, opsonized FIPV particles are internalized more efficiently by macrophages via Fc-gamma receptors, directly promoting viral replication within its target cell [11, 17]. This mechanism explains the historical failure of whole-virus vaccines for FIP, which primed the immune system for ADE rather than protection [6]. The risk of ADE remains a critical concern for coronavirus vaccine development across species, including for SARS-CoV-2 in humans, where suboptimal immunity can paradoxically worsen disease outcomes [17]. The robust serologic responses observed throughout antiviral treatment, documented by Murphy et al. [7], underscore the persistence of this humoral activation even as viral load declines, creating a sustained inflammatory potential.

Cellular Immunity and the Exhaustion Phenotype

The fate of the infected host hinges on the robustness of the cell-mediated immune (CMI) response. Cats that mount a strong, Th1-biased CMI response appear to control infection, while those that develop a weak CMI response are doomed to succumb to FIP [11]. The molecular basis of this failure is now well-characterized. A state of profound T-cell exhaustion is a central feature of FIP immunopathology.

Harun et al. [1] demonstrated a significant upregulation of the inhibitory receptor PD-1 and its ligand PD-L1 in FIPV-infected cells and in PBMCs from FIP-diagnosed cats. Wanakumjorn et al. [19] extended these findings, showing that cytotoxic T lymphocytes (CTLs) from FIP cats co-express multiple exhaustion markers, including PD-1, TIM-3, and LAG-3. This exhausted state is driven by specific transcription factors, such as IKZF2, ZEB2, and PRDM1, which are highly expressed in the lymphoid tissues of affected cats [19]. Single-cell RNA sequencing of mesenteric lymph nodes revealed that this exhaustion is reversible. Antiviral therapy with GS-441524 or remdesivir downregulates these inhibitory receptors and exhaustion-associated transcription factors while simultaneously upregulating memory T-cell markers like IL7R and GZMK [7, 19]. The inclusion of mesenchymal stem/stromal cell (MSC) therapy further enhanced immune recovery by expanding regulatory T-cell (Treg) populations, thereby promoting immune homeostasis and mitigating the dysregulated inflammation [19].

Macrophage Activation and the Cytokine Storm

The failure of CMI and the presence of ADE create a permissive environment for macrophages to become persistently infected and hyperactivated. The infected macrophage is the epicenter of the FIP cytokine storm. Lee et al. [13] performed comparative transcriptomic analyses on PBMCs from healthy, FIP-diseased, and FIP-recovered cats. They identified a critical role for the IL-8 signaling pathway and neutrophil degranulation in active disease, regulated upstream by the transcription factors KLF6 and NF-κB. This discovery highlights a significant neutrophilic component to FIP immunopathology that was previously underappreciated, suggesting that the inflammatory infiltrate is not purely macrophagic but involves a robust recruitment of neutrophils to sites of vascular injury. The sheer variety of cytokines and chemokines released, including IL-1β, IL-6, and TNF-α, drives the classic histologic and clinical manifestations of the disease [14].

The systemic inflammatory response disrupts the vascular endothelium, leading to the perivasculitis and pyogranulomatous inflammation that are the histopathologic hallmarks of FIP [7, 11]. Increased vascular permeability results in the accumulation of protein-rich effusions in the peritoneal, pleural, and pericardial cavities [7, 21]. Acute phase proteins, such as alpha-1 acid glycoprotein (AGP), are massively elevated in these effusions and serve as key diagnostic markers of the inflammatory process [14, 21].

Expanding the Inflammatory Target: Myocarditis and Neurologic Disease

The systemic nature of the FIP vasculitis and inflammation accounts for its multi-organ involvement, including the liver, pancreas, and kidneys [7]. Recent research has firmly established the heart and brain as critical targets of this immunopathologic process.

Myocarditis has emerged as a significant and potentially underdiagnosed component of FIP. Černá et al. [22] prospectively evaluated 20 cats with naturally occurring FIP and found that 55% had thickening of the left ventricular wall on echocardiography, while elevated cardiac troponin I (cTnI) levels served as a sensitive biomarker of myocardial injury. Korzybska et al. [21] described a case of effusive FIP that presented as congestive heart failure due to myocarditis and pericardial effusion. The complete resolution of these cardiac abnormalities following 12 weeks of GS-441524 treatment provides direct evidence that the myocardial inflammation is a direct consequence of active viral infection and the associated dysregulated immune response, rather than a separate idiopathic process. This mirrors the pathophysiology of COVID-19-associated myocarditis in humans.

Neurologic FIP is arguably the most challenging manifestation of the disease. The increased incidence of neurological signs in the FCoV-23 outbreak in Cyprus suggests that different viral strains may have enhanced neurotropism or the ability to evade immune surveillance within the central nervous system [4]. The pathogenesis involves the infection of perivascular macrophages and microglial cells, leading to localized inflammation in the brain parenchyma and choroid plexus.

Genetic and Environmental Determinants

Why do some cats exposed to FECV develop FIP while the vast majority do not? The answer lies at the intersection of host genetics and environmental pressure. The feline leukocyte antigen (FLA) complex governs antigen presentation. Addie et al. [16] investigated FLA-DRB polymorphism in cats and, while a clear allele-specific association was not established due to sample size and breed variation, the study pointed towards a significant genetic component. This is supported by clinical observations of overrepresentation of certain purebreds in FIP statistics [11, 16].

However, genetics alone do not tell the story. The high viral load and chronic stress typical of multi-cat environments like shelters and catteries are powerful co-factors that can overwhelm even a competent immune system, tipping the balance from benign carriage to lethal disease [9]. The virus can reside silently in blood cells, a state of equilibrium that can be shattered by immunosuppression or high-dose reinfection [10, 15]. The Centers for Disease Control and Prevention (CDC) and other public health bodies have highlighted the importance of studying such naturally occurring animal models to understand the complex host-pathogen interactions that govern the outcome of coronavirus infections, reinforcing the translational value of FIP research for human medicine.

Epidemiology and Transmission of Feline Coronavirus in Cat Populations

Feline coronavirus (FCoV) occupies a unique and paradoxical position within the pantheon of feline pathogens: it is simultaneously one of the most ubiquitous infectious agents of domestic cats and, in its mutated form, the cause of a near-uniformly fatal disease. Understanding the epidemiology and transmission dynamics of FCoV is not merely an academic exercise; it is the foundational prerequisite for designing effective biosecurity protocols, managing multicat environments, and interpreting the sporadic emergence of feline infectious peritonitis (FIP) outbreaks. The virus’s ecological success is built upon a trinity of factors: a remarkably efficient fecal-oral transmission route, a capacity for prolonged subclinical shedding, and a molecular mutability that, under specific host and environmental pressures, yields a highly lethal viral variant.

Global Seroprevalence and Population-Level Distribution

FCoV is globally enzootic, with seroprevalence rates that vary dramatically according to population density, husbandry practices, and geographic region. In low-density, single-cat households, seropositivity typically ranges from 20% to 40%, reflecting limited transmission opportunities. However, in multicat environments, including breeding catteries, rescue shelters, and high-density urban colonies, the prevalence of antibodies against FCoV frequently exceeds 90% [9, 23]. A serosurvey conducted in southern Brazil, testing 97 domestic cats from Pelotas, Rio Grande do Sul, found that exposure rates, as determined by serum neutralization assays, were heavily influenced by housing conditions; cats with access to the outdoors or living in multi-animal households had significantly higher odds of seropositivity [23]. This pattern is consistent with global data: FCoV is a pathogen of proximity. The virus thrives wherever cats share litter boxes, food bowls, or resting areas, and its transmission efficiency is inversely proportional to the square footage per cat.

The development of novel, high-throughput diagnostic tools has refined our ability to map seroprevalence at a population level. The recently described FCoVCHECK Ab ELISA, validated against the gold-standard immunofluorescence antibody test (IFAT), demonstrated a sensitivity of 93.5% and a specificity of 100%, offering a rapid and shelf-stable alternative for large-scale surveillance [20]. Such tools are critical for understanding the true burden of infection, as many FCoV-infected cats remain clinically normal and are thus invisible to passive surveillance. The World Organisation for Animal Health (WOAH) has recognized that coronaviruses of domestic animals, including FCoV, represent a paradigm for understanding viral emergence, as their high mutation rates and broad host range create a constant risk of novel variant generation.

Transmission Dynamics: The Fecal-Oral Route and Beyond

The primary axis of FCoV transmission is the fecal-oral route. The enteric biotype, feline enteric coronavirus (FECV), replicates predominantly in mature enterocytes lining the villi of the small intestine, from which large quantities of infectious virions are shed into the feces [9, 18]. In naive populations, the basic reproduction number (R₀) of FECV is exceptionally high, facilitating rapid invasion and near-universal infection within weeks of introduction. Experimental infections of specific-pathogen-free (SPF) cats with FECV strain UCD revealed that shedding of infectious virus begins as early as 4 days post-infection and persists for 28 to 56 days, with peak titers occurring in the first two weeks [10]. This protracted shedding period means that even transiently infected cats can contaminate their environment for weeks.

Critically, the infectiousness of shed virus is not static. Desmarets and colleagues demonstrated that virus recovered from feces during the later stages of infection (after approximately day 14) exhibited impaired infectivity in enterocyte cultures and was frequently affected by point mutations [10]. This observation has profound epidemiological implications: it suggests that at the population level, most transmission events occur early in the course of infection, when viral fitness in the gut is maximal. The later-phase shedding of less infectious variants may represent a dead end for transmission, or may reflect a shift in cellular tropism that precedes systemic invasion. Indeed, in one experimental cat, virus was detected in blood cells as early as 3 days post-infection, even in the absence of detectable intestinal replication, and this cell-associated viremia was followed by the sudden emergence of shed virus carrying non-enterotropic mutations [10]. This phenomenon, the gradual adaptation of FECV to monocytes and macrophages, constitutes the molecular bridge between a benign enteric infection and the potential for systemic disease.

Fomite transmission is equally significant. FCoV is enveloped and thus relatively labile in the environment, but under optimal conditions (cool, moist, protected from sunlight) it can remain infectious for weeks. Shared litter trays are the epicenters of transmission in shelter settings; the practice of scooping rather than completely replacing litter, or the use of multi-cat self-cleaning boxes, perpetuates viral circulation. The virus is also present in saliva, albeit at lower titers than in feces, which may facilitate transmission through shared food bowls or grooming.

The Internal Mutation Paradigm and Host Susceptibility

No discussion of FCoV epidemiology is complete without grappling with the central conundrum of FIP pathogenesis: why does a virus that infects virtually all cats cause fatal disease in only a minority (approximately 5–12% of seropositive animals)? The answer lies at the intersection of viral evolution and host genetics. The currently accepted model, supported by intrahost diversity analyses, posits that FIPV arises sporadically from the pre-existing FECV population within an individual cat through the accumulation of specific mutations, notably, but not exclusively, within the spike (S) protein gene [5, 8, 11]. Analysis of Italian FCoV sequences identified two amino acid substitutions, M1058L and S1060A, in the spike protein that were significantly associated with FIPV biotype; M1058L was detected in 16 of 18 type I FIPV strains and 1 of 1 type II FIPV strains, while S1060A was present in a smaller subset [5].

This internal mutation hypothesis has profound epidemiological consequences. It implies that FIP is not a contagious disease in the traditional sense. The FIPV biotype is not efficiently transmitted horizontally; cats do not "catch FIP" from one another. Rather, each case of FIP represents an independent, stochastic mutational event occurring within a cat that is already infected with the benign enteric form. This explains the puzzling epidemiological pattern observed in catteries: high-density populations have both high FECV seroprevalence and a higher incidence of FIP, yet the FIP cases often appear sporadically and unpredictably, without clear chains of transmission. Sequencing of the membrane (M) gene from 190 samples taken from 10 cats with FIP and 5 unaffected cats confirmed that multiple distinct FCoV lineages can coexist within a single animal, and that the systemic (FIP-associated) lineage often segregates phylogenetically from the enteric lineage present in the same host [8]. This segregation is consistent with the emergence of a virulent mutant from a quasispecies pool, rather than the introduction of a novel exogenous strain.

Host genetic factors modulate the probability that such mutations lead to clinical disease. The feline leucocyte antigen (FLA) complex, analogous to the human HLA system, plays a central role in antigen presentation and immune recognition. A preliminary study of FLA-DRB polymorphism in 25 cats found that certain alleles and allele combinations were overrepresented among FIP-affected cats, although the small sample size precluded definitive statistical associations [16]. Pedigree cats, which often have reduced genetic diversity due to line-breeding, are overrepresented in FIP case series; whether this reflects true genetic susceptibility or simply the higher viral loads and stress levels inherent to cattery life remains a matter of debate [11]. Nevertheless, the identification of immune-related transcriptional signatures, including dysregulation of PD-1, PD-L1, and A3H genes in peripheral blood mononuclear cells of FIP-diagnosed cats, points toward a host-pathogen interaction that is finely balanced, where minor genetic variations can tip the scales toward immunopathology versus viral clearance [1, 13].

Epizootic Emergence and the Cyprus Model

The epidemiological landscape of FCoV was dramatically reshaped in 2023 by the emergence of a large-scale FIP epizootic in Cyprus, temporally associated with a novel recombinant FCoV variant designated FCoV-23. Prospective surveillance conducted by Epaminondas and colleagues, using a structured questionnaire implemented in veterinary management software, captured data from 68 FIP cases reported by 22 clinics across the island [4]. Several features of this outbreak challenge conventional epidemiological wisdom. The mean age of affected cats was 3.9 years (median 3.0; range 0.4–12.9 years), markedly older than the typical FIP demographic (which peaks at under 2 years of age). This age shift suggests that the variant may possess an altered virulence profile, capable of overcoming age-related resistance, or that the outbreak was driven by a recently introduced pathogen to which older cats had no prior immunity.

Geographically, the outbreak was concentrated in the coastal city of Limassol (51.5% of cases) and the capital Nicosia (25.0%), consistent with introduction through a major port or densely populated urban center [4]. Neurological manifestations were documented in 35.3% of cases, a proportion that far exceeds the typical 5–10% observed in sporadic FIP. This neurotropism is a hallmark of FCoV-23 and has been linked to specific mutations in the spike gene that enhance the virus’s ability to cross the blood-brain barrier. The epizootic also highlighted the critical role of antiviral access: 92.2% of diagnosed cats received GS-441524 or molnupiravir, with 88.9% demonstrating clinical improvement. This real-world efficacy underscores the need for rapid diagnostic deployment during epizootic events.

The Cyprus outbreak serves as a sentinel event for coronavirology. It demonstrates that FCoV, long considered a relatively stable virus with predictable mutation patterns, retains the capacity for punctuated emergence of highly pathogenic variants. For global health authorities, including the World Health Organization (WHO) and the WOAH, such events underscore the importance of continuous genomic surveillance of coronaviruses in domestic animals, as they provide a living laboratory for understanding the mechanisms of host-switching, recombination, and virulence emergence that have driven pandemics in human populations [17].

Transmission in Multicat Environments and the Role of Stress

Shelters, catteries, and rescue facilities are the crucibles within which FCoV transmission is most intense and FIP risk is highest. In these settings, the interplay of high viral load, co-mingling of cats from diverse origins, and physiological stress creates a perfect storm. Stress, whether from overcrowding, nutritional deficiency, concurrent disease, or the social disruption of rehoming, is a well-established risk factor for the progression from FECV carriage to FIP [9, 11]. Glucocorticoid-mediated immunosuppression is thought to tip the balance of monocyte/macrophage permissiveness to FCoV replication, allowing the mutated FIPV to gain a foothold.

Management interventions aimed at breaking the transmission cycle have been the mainstay of control for decades, yet they remain incompletely effective. Segregation of cats by age group (weanlings, juveniles, adults) and the use of cohort housing with dedicated litter boxes and feeding equipment can reduce transmission pressure. However, the prolonged shedding period and the possibility of transient, cell-associated viremia, which may allow spread via blood-contaminated fomites or even through arthropod vectors, though this remains speculative, make eradication within a facility extraordinarily difficult. The development of rapid, point-of-care diagnostic tests, such as the FCoVCHECK Ab ELISA, offers a practical tool for identifying recently infected cats and implementing isolation protocols before widespread environmental contamination occurs [20]. For high-risk populations, the goal of management is not to achieve FCoV-free status (an unrealistic target in most facilities) but to minimize the incidence of FIP by reducing viral dose, stress, and genetic susceptibility.

FCoV epidemiology is a dynamic tapestry woven from virological, environmental, and host threads. The virus’s ability to persist as a silent, subclinical infection in the majority of its hosts, while occasionally unleashing a devastating systemic disease, makes it a model system for understanding the evolutionary pressures that shape coronavirus virulence. The global distribution of FCoV, its high prevalence in managed populations, and its capacity for punctuated epizootic emergence demand ongoing vigilance from veterinary practitioners, shelter operators, and public health agencies alike.

Diagnostic Approaches for Feline Coronavirus Infection and FIP: Serology and Molecular Assays

The diagnosis of feline infectious peritonitis (FIP) remains one of the most formidable challenges in contemporary veterinary medicine, a reality underscored by the enduring complexity of the host-pathogen interaction [11]. The central diagnostic dilemma arises from the fact that the causative agent, the FIP virus (FIPV), is a virulent mutant biotype of the ubiquitous and largely benign feline enteric coronavirus (FECV). No single laboratory test can reliably distinguish between these two biotypes in a clinical setting [9, 11, 12]. Consequently, a definitive antemortem diagnosis of FIP is rarely established through a single assay; rather, it is achieved through the cumulative integration of signalment, history, clinical signs, clinicopathological abnormalities, and a suite of serological and molecular tests, a process aptly described as building a diagnostic case “brick by brick” [14]. This section provides an exhaustive analysis of the serological and molecular approaches available, critically evaluating their biological principles, performance characteristics, and diagnostic limitations within the context of FCoV infection and FIP pathogenesis.

Serological Assays: Antibody Detection and Its Limitations

Serological testing for anti-FCoV antibodies represents a cornerstone of the diagnostic workup, yet its interpretation is fraught with nuance. The rationale for serology is straightforward: the detection of antibodies indicates prior or current exposure to FCoV. However, in a population where FECV is endemic, particularly in multicat environments where seroprevalence can exceed 90%, a positive antibody test is of limited value for confirming FIP, as a vast majority of seropositive cats will never develop the disease [11, 16, 23]. The diagnostic value lies instead in the negative predictive value: a truly seronegative cat with clinical signs consistent with FIP is unlikely to have the disease, as the robust humoral immune response typical of FCoV infection is almost invariably present in FIP cases [7, 11].

The gold standard reference method for serology has historically been the indirect immunofluorescence antibody test (IFAT), which utilizes FCoV-infected cells as a substrate to detect antibodies, primarily of the IgG isotype, directed against viral structural proteins, most notably the nucleocapsid (N) and membrane (M) proteins [7, 20]. IFAT, while reliable, is labor-intensive, subjective, and not standardized across laboratories, prompting the development of alternative enzyme-linked immunosorbent assays (ELISAs). A significant recent advancement is the development of a new rapid indirect ELISA, designated FCoVCHECK Ab ELISA, which has demonstrated excellent performance when compared to IFAT as the reference standard [20]. In a comprehensive evaluation, this assay exhibited a sensitivity of 93.5% (95% CI: 83.5–97.9%) and a specificity of 100% (95% CI: 90.8–100%), with an overall agreement of 96.4% [20]. This assay offers practical advantages, including a rapid 1-hour turnaround, safe reagents, long-term stability at 2-8°C (up to 18 months), and no requirement for specialized thermostats, making it highly suited for point-of-care use in veterinary clinics [20]. Its performance was also superior to that of two widely used commercial ELISAs, representing a meaningful improvement in diagnostic serology [20].

Despite these advances, the biological interpretation of serological results must be grounded in an understanding of the FIP immunopathogenesis. The antibody response in FIP is characteristically robust and persistent, predominantly of the IgG isotype, and is largely directed against the N and M proteins, with a lesser response to the spike (S) protein [7]. Studies of cats enrolled in antiviral clinical trials have shown that these anticoronaviral serologic responses remain stable and robust throughout the treatment period and into remission, with similar patterns observed in effusions and serum or plasma [7]. Interestingly, no significant differences in serological profiles were observed between cats that died or were euthanized and those that entered remission, underscoring that the presence of antibodies alone does not dictate disease outcome [7]. This persistence also complicates the use of serology to monitor treatment response. In the context of the 2023 FCoV-23 epizootic in Cyprus, serological approaches were not the primary diagnostic tool, but the clinical presentations, including an unusually high proportion of neurological cases and an older median age of affected cats (3.9 years), highlighted the need for serological assays that can keep pace with emerging viral variants [4]. The reliance on antibody detection also raises the specter of antibody-dependent enhancement (ADE), a phenomenon first described in the context of FIP vaccine trials where non-neutralizing antibodies facilitated viral entry into macrophages, exacerbating disease [17]. While ADE is a critical consideration for vaccine design, it does not directly limit the diagnostic utility of serology, though it does inform the biological complexity of the immune response being measured.

Molecular Assays: RT-PCR, Viral Load Quantification, and the Quest for Biotype Differentiation

Molecular diagnostic techniques, particularly reverse transcription polymerase chain reaction (RT-PCR), have become indispensable in the FIP diagnostic armamentarium, offering the ability to detect viral nucleic acids directly [12, 14]. The fundamental challenge, mirroring that of serology, is that RT-PCR assays cannot inherently distinguish between the FECV and FIPV biotypes; they detect the presence of FCoV RNA, which could originate from either a benign enteric infection or a lethal systemic disease [9, 12]. The diagnostic strategy, therefore, hinges on the selection of the biological sample and the interpretation of the viral load and its location.

The greatest diagnostic utility is derived from analyzing samples obtained from the sites of pathological inflammation characteristic of FIP. In cats with the effusive (“wet”) form of the disease, analysis of thoracic or abdominal effusions provides the highest yield. A quantitative RT-PCR (qRT-PCR) assay performed on ascites fluid or pleural fluid can detect viral RNA with high sensitivity [7, 21]. For instance, in a case of FIP-associated myocarditis, a positive qRT-PCR result on pleural fluid, in conjunction with a highly proteinaceous exudate (84.3 g/L) and markedly elevated serum alpha-1 acid glycoprotein (AGP), confirmed the diagnosis of effusive FIP [21]. Furthermore, in a cohort of 34 FIP cats enrolled in clinical trials, normalized tissue or effusion viral loads were readily quantifiable using qRT-PCR, and all viral isolates were confirmed as serotype I FIPV [7]. Critically, in cats treated with antiviral compounds (GS-441524, remdesivir), viral nucleic acids in ascites or abdominal lymph node tissue became undetectable by sensitive qRT-PCR by 11 days post-treatment, demonstrating the assay's utility in monitoring therapeutic response and viral clearance [7]. This rapid decline to undetectability underscores the dynamic nature of viral replication in FIP. However, it is equally important to note that FIP-associated viral loads may still be below the detection threshold of some assays, particularly in the non-effusive (“dry”) form, where the viral burden can be more sequestered within pyogranulomatous lesions [14].

The use of whole blood or serum for RT-PCR is markedly less reliable for diagnosing FIP. The virus is cell-associated and circulates within infected monocytes and macrophages, but the levels in peripheral blood are often low or intermittent. Indeed, early studies demonstrated that FCoV mRNA could be detected by RT-PCR in the blood of a significant proportion (54%) of healthy cats, including those from a population where one cat exhibited clinical FIP, indicating a poor specificity for FIP diagnosis when using blood as a sample [15]. This cell-associated viraemia is a hallmark of FECV infection as well, with experimental studies showing that FECV can be detected in blood cells even in the absence of intestinal replication, raising the hypothesis that a gradual adaptation to cells of the monocyte/macrophage lineage allows non-enterotropic mutants to arise [10]. Therefore, a positive RT-PCR result from blood does not confirm a diagnosis of FIP, nor does a negative result rule it out.

One of the most active and controversial areas of molecular diagnostics involves the detection of specific viral mutations that are hypothesized to confer the pathogenic (FIP) phenotype. For decades, the “internal mutation hypothesis” has been the central paradigm, positing that FIPV arises from FECV through the acquisition of specific point mutations within the host [8, 11]. The spike (S) protein, which governs cellular tropism, has been the primary focus. Two amino acid substitutions, M1058L and S1060A, within the S protein were initially proposed as key virulence markers [5]. However, field studies in Italy revealed a complex picture: while the M1058L mutation was detected in 16/18 type I FIPV strains and 1/1 type II FIPV strains, it was not universally present, and the S1060A change was only found in two FIPV strains [5]. This suggests that these mutations are neither necessary nor sufficient for virulence, and that other genetic determinants, or perhaps a constellation of multiple mutations, are at play. The intrahost diversity of FCoV is substantial, as demonstrated by sequencing of the membrane (M) gene, which revealed that in one cat, two distinct FCoV lineages, one enteric and one systemic, could be found, supporting the notion that multiple FIPV quasispecies can co-exist and evolve within a single animal [8]. This genetic plasticity poses a significant challenge for designing a single PCR assay that targets a specific, conserved virulence mutation [14]. Laboratories offering such mutation-specific PCR assays must be interpreted with caution; a negative result does not exclude FIP, as the requisite mutation may not be the one being targeted, and a positive result, while suggestive, is not yet proven to be pathognomonic [14]. The 2022 AAFP/EveryCat Feline Infectious Peritonitis Diagnosis Guidelines emphasize this point, advising clinicians that the interpretation of PCR results must be contextualized within the full clinical picture [14].

Emerging transcriptomic approaches offer a new dimension to molecular diagnostics. Comparative transcriptome analysis of peripheral blood mononuclear cells (PBMCs) from healthy, FIP-diseased, and FIP-recovered cats has identified distinct mRNA expression signatures [13]. This research revealed statistically significant and contrasting patterns in canonical pathways, particularly neutrophil degranulation and IL-8 signaling, driven by upstream regulators such as KLF6 and NF-κB [13]. Moreover, transcriptional profiling of FIPV infection in CRFK cells and PBMCs from FIP-diagnosed cats has identified upregulation of genes like PD-L1 and A3H, which are associated with monocyte-macrophage function and apoptosis [1]. While these transcriptomic signatures are not yet validated as clinical diagnostic tests, they represent a promising frontier for developing biomarker-based assays that could identify FIP-specific immune dysregulation patterns, moving beyond the simple detection of viral nucleic acids. The integration of these molecular and serological approaches, guided by an understanding of viral pathogenesis and epidemiology, remains the most robust strategy for navigating the diagnostic complexity of FIP.

Antiviral Therapies and Future Perspectives for FIP Management

The management of feline infectious peritonitis (FIP) has undergone a revolutionary paradigm shift over the past five years, transitioning from a uniformly fatal diagnosis with no effective interventions to a condition that is now increasingly treatable with targeted antiviral chemotherapy. This transformation, driven largely by the repurposing of nucleoside analogue inhibitors developed for human viral diseases and the serendipitous application of protease inhibitors, has fundamentally altered the clinical landscape for affected cats. However, despite these remarkable advances, significant challenges remain regarding optimal dosing regimens, management of drug-resistant viral variants, treatment of neurological and ocular forms of the disease, and the development of strategies that address the profound immune dysregulation that characterizes FIP pathogenesis. A comprehensive understanding of the currently available antiviral arsenal, the immunological rationale for adjunctive therapies, and the emerging frontiers of drug discovery is essential for clinicians and researchers alike.

The Nucleoside Analogue Revolution: GS-441524, Remdesivir, and Molnupiravir

The cornerstone of contemporary FIP therapy is the nucleoside analogue GS-441524, the parent nucleoside of remdesivir, which functions as a competitive inhibitor of viral RNA-dependent RNA polymerase (RdRp) by mimicking adenosine triphosphate and causing delayed chain termination during viral replication [6, 7, 13]. The mechanistic superiority of GS-441524 over remdesivir for feline applications stems from its superior oral bioavailability and favorable pharmacokinetic profile in cats, permitting convenient oral administration at doses of 10 mg/kg every 12 hours for a standard 12-week course [21]. The clinical efficacy of this approach has been overwhelmingly demonstrated across multiple independent clinical trials and retrospective case series. In a comprehensive analysis of 60 client-owned cats with naturally occurring FIP enrolled in antiviral clinical trials at the University of California, Davis, treatment with GS-441524 achieved remarkable rates of clinical remission, with viral RNA in ascites or abdominal lymph node tissue becoming undetectable by quantitative RT-PCR as early as 11 days post-treatment initiation [7]. The same study documented that 14 of 60 treated cats (23.3%) either died or were euthanized during or after treatment, indicating that while highly effective, the therapy is not universally successful, and that severe disease, particularly with extensive neurological involvement, remains a significant therapeutic challenge [7].

GS-441524 therapy has demonstrated efficacy across the spectrum of FIP clinical presentations, including in cases with previously unrecognized cardiac involvement. In a landmark case report of a 4-year-old domestic shorthair cat with FIP-associated myocarditis characterized by generalized left ventricular hypertrophy, left atrial enlargement, pleural effusion, and markedly elevated cardiac troponin I (1.31 ng/mL; reference interval <0.05 ng/mL), treatment with GS-441524 at 10 mg/kg PO q12h for 12 weeks resulted in complete resolution of clinical signs, normalization of serum alpha-1 acid glycoprotein (AGP), and, remarkably, full reversal of cardiac remodelling [21]. This observation aligns with prospective echocardiographic and biomarker studies demonstrating that elevated cardiac troponin I and ventricular wall thickening in cats with FIP normalize following successful antiviral therapy, suggesting that myocardial injury associated with FIP is reversible with effective viral suppression [22]. The broader epidemiological significance of this finding is underscored by the observation that during the 2023 FIP epizootic in Cyprus associated with the novel recombinant FCoV-23 strain, antiviral therapy with GS-441524 or molnupiravir was administered in 92.2% of documented cases, with reported clinical improvement in 88.9% of treated animals, despite an increased proportion of neurological presentations that typically portend a poorer prognosis [4].

Molnupiravir, another nucleoside analogue that acts as a prodrug of the ribonucleoside analogue N-hydroxycytidine (NHC), has also demonstrated clinical utility in FIP management, particularly in cases where GS-441524 is unavailable or where cost considerations are paramount [4, 7]. The mechanism of action of molnupiravir involves the incorporation of NHC triphosphate into viral RNA by the RdRp, leading to catastrophic mutagenesis through the accumulation of lethal errors in the viral genome. Data from the Cyprus epizootic indicate that molnupiravir was employed as a first-line or alternative therapy in a subset of cases, contributing to the overall high rate of clinical improvement observed [4]. However, comparative head-to-head trials evaluating the relative efficacy, safety, and durability of response between GS-441524 and molnupiravir remain limited, and the potential for differential tissue penetration, particularly across the blood-brain barrier, warrants further investigation given the high frequency of neurological FIP in contemporary outbreaks.

Protease Inhibitors: GC376 and the 3CLpro Target

Complementing the nucleoside analogue approach is the development of protease inhibitors targeting the viral 3C-like protease (3CLpro, also designated Mpro), an essential enzyme responsible for the proteolytic processing of the viral polyprotein into functional nonstructural proteins required for replication complex assembly [2, 6]. The feline coronavirus 3CLpro represents an exceptionally attractive drug target due to its high degree of conservation across coronavirus species, its essential role in viral replication, and the absence of a closely related host protease, thereby minimizing the potential for off-target toxicity. The inhibitor GC376, a peptidomimetic compound targeting the 3CLpro active site, has been evaluated in experimental and clinical settings, demonstrating antiviral activity against FCoV in vitro and in naturally infected cats [6]. While GC376 has shown clinical efficacy, particularly in cases without significant neurological involvement, its use has been associated with certain limitations, including the requirement for parenteral administration, potential for injection site reactions, and the emergence of drug resistance associated with mutations in the 3CLpro coding sequence.

The continued search for optimized 3CLpro inhibitors has been substantially advanced by computational approaches. A comprehensive structure-based virtual screening study employing a library of 96,677 natural compounds from the ZINC database utilized molecular docking, ADMET property evaluation, and 100-nanosecond molecular dynamics simulations to identify candidate inhibitors of FCoV 3CLpro [2]. This rigorous computational pipeline yielded 14 compounds exhibiting strong interaction stability and minimal conformational fluctuation, with eight of these maintaining stable binding profiles throughout extended 500-nanosecond molecular dynamics simulations and exhibiting elevated binding free energy values [2]. The analysis of binding modes revealed that key active site residues, including His162, Glu165, and Cys144, formed crucial hydrogen bonds and hydrophobic contacts contributing to complex stability [2]. The identification of core molecular frameworks from this study provides an initial reference for the rational design of next-generation FCoV 3CLpro inhibitors, potentially yielding compounds with improved oral bioavailability, enhanced central nervous system penetration, and reduced susceptibility to protease mutations. The structural insights gained from this work also have broader implications, given the phylogenetic relationships between FCoV and SARS-CoV-2. Studies have demonstrated that FIPV isolates from naturally infected cats cluster together with SARS-CoV-2 Clade A, Clade D, and Clade F strains in phylogenetic analyses, indicating shared evolutionary trajectories that may render cross-reactive protease inhibitors feasible [3].

Immunomodulatory Adjunctive Therapy: Mesenchymal Stem/Stromal Cells

While direct-acting antiviral agents effectively suppress viral replication, the immunopathological mechanisms driving FIP, including T-cell exhaustion, lymphopenia, systemic inflammation, and immune dysregulation, require adjunctive therapeutic approaches to achieve complete immune reconstitution and prevent long-term sequelae [19]. The rationale for immunomodulatory therapy in FIP stems from the profound alterations in the host immune response documented at the transcriptomic level. RNA sequencing of FIPV-infected CRFK cells and peripheral blood mononuclear cells (PBMCs) from FIP-diagnosed cats revealed differential expression of 61 genes, including upregulation of programmed death-1 (PD-1), programmed death ligand-1 (PD-L1), and apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3H (A3H), implicating T-cell exhaustion and innate antiviral responses in disease pathogenesis [1]. Furthermore, comparative transcriptome analysis of PBMCs from normal, FIP-diseased (FIPD), and FIP-recovered (FIPR) cats identified 677 differentially expressed genes (FIPD vs. Normal) and 431 differentially expressed genes (FIPR vs. FIPD), with statistically significant and contrasting patterns in neutrophil degranulation and interleukin-8 (IL-8) signaling pathways, regulated by kruppel-like factor 6 (KLF6) and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) [13]. These findings indicate that successful antiviral therapy alone may be insufficient to fully reverse the immunological damage inflicted during active FIPV infection.

Mesenchymal stem/stromal cell (MSC) therapy represents a promising immunomodulatory adjunct that addresses the immune dysfunction underlying FIP. In a rigorous experimental study evaluating allogeneic MSC therapy combined with antiviral treatment in cats with effusive FIP, hematologic, virologic, and immunologic analyses conducted over 12 weeks revealed that antiviral therapy alone reduced cytotoxic T-cell exhaustion by downregulating inhibitory receptors PD-1, TIM-3, and LAG-3 [19]. However, cats receiving MSC therapy demonstrated enhanced immune recovery, evidenced by reduced expression of exhaustion-related transcription factors (IKZF2, ZEB2, PRDM1) and increased regulatory T-cell (Treg) populations, promoting immune homeostasis [19]. Single-cell RNA sequencing of mesenteric lymph nodes from MSC-treated cats revealed transcriptomic shifts indicative of immune rejuvenation, including elevated memory T-cell markers (IKZF1, GZMK, IL7R) and reduced hyperproliferative lymphocyte subsets [19]. Serum cytokine analysis using principal component analysis identified three distinct inflammatory mediator patterns, and while both treatment groups showed transitions toward cytokine profiles resembling those of healthy controls, residual cytokine elevations persisted at the study's end, mirroring features of chronic immune dysregulation [19]. Notably, platelet-derived growth factor BB (PDGF-bb), a marker of tissue repair, was uniquely associated with higher lymphocyte counts in MSC-treated cats, suggesting a specific role in lymphoid recovery [19]. These findings underscore the translational relevance of MSC therapy for addressing severe viral diseases characterized by chronic inflammation and immune dysregulation, and they suggest that optimal FIP management may require a combinatorial approach integrating direct-acting antivirals with immunomodulatory agents.

Emerging Antiviral Targets and Future Drug Development

The landscape of FIP therapeutics continues to expand through innovative drug discovery approaches targeting additional viral and host factors. Beyond the established RdRp and 3CLpro targets, the viral spike (S) protein represents a critical target for therapeutic intervention, given its essential role in receptor binding and viral entry [5]. The S protein of FCoV undergoes specific amino acid substitutions associated with the FECV-to-FIPV virulence switch, particularly mutations M1058L and S1060A within the spike protein, which have been identified in Italian FCoV strains and are associated with systemic dissemination [5]. The development of compounds that disrupt S protein-mediated membrane fusion or receptor binding, including VNAR antibody therapies derived from shark immunoglobulin new antigen receptor technology, represents a promising avenue for future drug development [6]. These biologics offer advantages including small size, high stability, and the ability to target epitopes inaccessible to conventional antibodies, potentially enabling therapeutic neutralization of FCoV even in immunologically privileged sites such as the central nervous system.

Lysosomal pH modulators, including chloroquine and hydroxychloroquine, have also been investigated for FIP treatment based on their ability to inhibit viral entry by raising endosomal pH and disrupting membrane fusion [6]. However, the clinical efficacy of these agents in FIP has been variable, and concerns regarding toxicity, particularly retinal accumulation and cardiotoxicity with prolonged use, have limited their widespread adoption. The future of FIP pharmacotherapy likely lies in combination therapy regimens that target multiple stages of the viral life cycle, entry, protease-mediated polyprotein processing, and RNA replication, while simultaneously modulating the host immune response to promote viral clearance and immune reconstitution.

The Challenge of FCoV-23 and Future Epizootic Preparedness

The emergence of the novel recombinant FCoV-23 strain in Cyprus during 2022-2025 and the associated large-scale FIP epizootic has highlighted critical gaps in our preparedness for managing FIP outbreaks, particularly those involving viral strains with altered tropism and pathogenicity [4]. Epidemiological analysis of 68 veterinarian-reported cases during the Cypriot epizootic revealed that affected cats were older than typically reported for FIP (mean age 3.9 years; median 3.0; range 0.4–12.9 years), and that neurological and ocular manifestations were documented in 35.3% of cases, representing a significantly higher proportion than in historical cohorts [4]. While GS-441524 and molnupiravir therapy achieved clinical improvement in 88.9% of treated cases, the increased neurological involvement suggests that current antiviral regimens may require dose adjustments or extended treatment duration to achieve adequate central nervous system penetration and viral clearance. The molecular characterization of FCoV-23 as a recombinant virus underscores the plasticity of coronavirus genomes and the potential for future emergence of strains with altered antiviral susceptibility profiles [4].

The translational significance of FIP research extends beyond feline medicine to human coronavirus disease management. The immunological parallels between FIP and severe COVID-19, including T-cell exhaustion, cytokine storm, and antibody-dependent enhancement (ADE), have been recognized by the World Health Organization and the scientific community as important areas for cross-species investigation [17]. The successful application of nucleoside analogues and immunomodulatory therapies in FIP provides a valuable naturally occurring animal model for evaluating therapeutic strategies applicable to severe SARS-CoV-2 infection in humans. As the International Committee on Taxonomy of Viruses continues to refine the classification of coronaviruses within the Nidovirales order, the fundamental insights gained from FIP research into coronavirus pathogenesis, immune evasion, and antiviral drug development will remain critically relevant to both veterinary and human medicine [18]. The ongoing surveillance of FCoV strains circulating in domestic cat populations, utilizing tools such as the newly developed FCoVCHECK Ab ELISA for serological monitoring, will be essential for detecting the emergence of novel variants and informing timely therapeutic interventions [20].

References

[1] Harun MSR, Kuan CO, Selvarajah GT, Wei T, Arshad S, Bejo M, et al.. Transcriptional profiling of feline infectious peritonitis virus infection in CRFK cells and in PBMCs from FIP diagnosed cats. Virology Journal. 2013. DOI: https://doi.org/10.1186/1743-422X-10-329

[2] Jiang Z, Chen H, Xiong W, Zhang W, Zhu Y, Kong R. Natural Product-Based Virtual Screening Identifies Potential Inhibitors of Feline Coronavirus 3CLpro.. Current Topics in Medicinal Chemistry. 2026. DOI: https://doi.org/10.2174/0115680266426906251125112131

[3] Aksono E, Iradatya KR, Sucipto TH, Fajar N, Yuniarti W. Phylogenetic analysis of feline infectious peritonitis virus, feline enteric coronavirus, and severe acute respiratory syndrome coronavirus 2 of cats in Surabaya, Indonesia. Veterinary World. 2023. DOI: https://doi.org/10.14202/vetworld.2023.76-81

[4] Epaminondas D, Mazeri S, Lyraki M, Tait-Burkard C, Gunn-Moore D, Loukaidi S, et al.. Epidemiological and Clinical Insights from 68 Veterinarian-Reported Cases of Feline Infectious Peritonitis During the Documented FIP Epizootic in Cyprus. Pathogens. 2026. DOI: https://doi.org/10.3390/pathogens15050499

[5] Decaro N, Mari V, Lanave G, Lorusso E, Lucente M, Desario C, et al.. Mutation analysis of the spike protein in Italian feline infectious peritonitis virus and feline enteric coronavirus sequences.. Research in Veterinary Science. 2021. DOI: https://doi.org/10.1016/j.rvsc.2020.12.023

[6] Wang C. Diagnosis and Treatment of Feline Infectious Peritonitis. Theoretical and Natural Science. 2025. DOI: https://doi.org/10.54254/2753-8818/2025.au22989

[7] Murphy B, Castillo D, Neely NE, Kol A, Brostoff T, Grant C, et al.. Serologic, Virologic and Pathologic Features of Cats with Naturally Occurring Feline Infectious Peritonitis Enrolled in Antiviral Clinical Trials. Viruses. 2024. DOI: https://doi.org/10.3390/v16030462

[8] Hora AS, Asano KM, Guerra J, Mesquita RG, Maiorka P, Richtzenhain L, et al.. Intrahost Diversity of Feline Coronavirus: A Consensus between the Circulating Virulent/Avirulent Strains and the Internal Mutation Hypotheses?. TheScientificWorldJournal. 2013. DOI: https://doi.org/10.1155/2013/572325

[9] Drechsler Y, Alcaraz A, Bossong F, Collisson E, Diniz P. Feline Coronavirus in Multicat Environments. The Veterinary clinics of North America. Small animal practice. 2011. DOI: https://doi.org/10.1016/j.cvsm.2011.08.004

[10] Desmarets L, Vermeulen B, Theuns S, Conceição-Neto N, Zeller M, Roukaerts IDM, et al.. Experimental feline enteric coronavirus infection reveals an aberrant infection pattern and shedding of mutants with impaired infectivity in enterocyte cultures. Scientific Reports. 2016. DOI: https://doi.org/10.1038/srep20022

[11] Pedersen N. An update on feline infectious peritonitis: Virology and immunopathogenesis. The Veterinary Journal. 2014. DOI: https://doi.org/10.1016/j.tvjl.2014.04.017

[12] Soma T. Feline Coronavirus RT-PCR Assays for Feline Infectious Peritonitis Diagnosis. Animal Coronaviruses. 2015. DOI: https://doi.org/10.1007/978-1-4939-3414-0_15

[13] Lee JY, Cho HR, Oh H, Hwang JH. Comparative transcriptome analysis of PBMCs in cats diagnosed with and recovered from FIPV. Laboratory Animal Research. 2025. DOI: https://doi.org/10.1186/s42826-025-00247-5

[14] Thayer V, Gogolski SM. Rising to the challenge of FIP diagnosis. Journal of feline medicine and surgery. 2022. DOI: https://doi.org/10.1177/1098612X221118746

[15] Can-Sahna K, Ataseven V, Pinar D, Oğuzoğlu T. The detection of feline coronaviruses in blood samples from cats by mRNA RT-PCR. Journal of feline medicine and surgery. 2007. DOI: https://doi.org/10.1016/j.jfms.2007.03.002

[16] Addie D, Kennedy L, Ryvar R, Willoughby K, Gaskell R, Ollier W, et al.. Feline leucocyte antigen class II polymorphism and susceptibility to feline infectious peritonitis. Journal of feline medicine and surgery. 2004. DOI: https://doi.org/10.1016/j.jfms.2003.12.010

[17] Pattnaik B, Yadav MP. Covid-19 pandemic: History, aetiology, epidemiology, vaccinology and societal impact. Indian Journal of Comparative Microbiology, Immunology and Infectious Diseases. 2020. DOI: https://doi.org/10.5958/0974-0147.2020.00001.x

[18] Horzinek MC. The bright future of coronavirology. Journal of feline medicine and surgery. 2004. DOI: https://doi.org/10.1016/j.jfms.2004.01.004

[19] Wanakumjorn P, Kimura K, Castillo D, McLarty E, Formaker R, Qiao R, et al.. Mesenchymal stem/stromal cell therapy improves immune recovery in a feline model of severe coronavirus infection. Stem Cells Translational Medicine. 2025. DOI: https://doi.org/10.1093/stcltm/szaf025

[20] Ferrero I, Dewilde S, Poletti P, Canepa B, Giachino E, Dall'Ara P, et al.. Development of a New Indirect ELISA Test for the Detection of Anti-Feline Coronavirus Antibodies in Cats. Veterinary Sciences. 2025. DOI: https://doi.org/10.3390/vetsci12030245

[21] Korzybska E, O’Halloran C, Culshaw GJ, Milevoj N, Fernandez-Gallego A, Oliveira MI. Successful treatment of feline infectious peritonitis-associated myocarditis in a cat. JFMS open reports. 2025. DOI: https://doi.org/10.1177/20551169251366442

[22] Černá P, Ross ES, Visser L, Ellis-Reis R, Willis M, Hawley J, et al.. Descriptive assessment of cardiac changes in cats with feline infectious peritonitis. Journal of Veterinary Internal Medicine. 2026. DOI: https://doi.org/10.1093/jvimsj/aalag083

[23] Johann JM, Caetano CF, Hass R, Guim TN, Fischer G, Vargas G, et al.. Serum survey for antibodies to coronavirus, herpesvirus, calicivirus, and parvovirus in domestics cats from Rio Grande do Sul, Brazil. Arquivo Brasileiro De Medicina Veterinaria E Zootecnia. 2009. DOI: https://doi.org/10.1590/S0102-09352009000300033